Ecopipam - CAS 112108-01-7
Catalog number: 112108-01-7
Category: Inhibitor
Please be kindly noted products are not for therapeutic use. We do not sell to patients.
Molecular Formula:
C19H20ClNO
Molecular Weight:
313.83
COA:
Inquire
Targets:
Dopamine Receptor
Description:
Ecopipam, a synthetic benzazepine derivative drug, acts as a selective dopamine D1/D5 receptor antagonist with little affinity for either dopamine D2-like or 5-HT2 receptors. It was developed by Schering plough. It is currently in clinical trials conducted by the biotechnology company Psyadon Pharmaceuticals for the treatment of Tourette syndrome in children. It has received FDA treatment of Lesch-Nyhan disease orphan drug certification.
Purity:
>98%
Appearance:
Solid powder
Synonyms:
Sch 39166;(6aS)-11-Chloro-6,6aβ,7,8,9,13bα-hexahydro-7-methyl-5H-benzo[d]naphth[2,1-b]azepin-12-ol;(6aβ,13bα)-11-Chloro-6,6a,7,8,9,13b-hexahydro-7-methyl-5H-benzo[d]naphth[2,1-b]azepin-12-ol;5H-Benzo(D)naphth(2,1-B)azepin-12-ol, 11-chloro-6,6A,7,8,9,13B-hexahydro-7-methyl-, trans-(-)-;6,7,7A,8,9,13B-Hexahydro-3-chloro-2-hydroxy-N-methyl-5H-benzo(D)naphtho(2,1B)azepine;(6aS,13bR)-11-chloro-7-methyl-5,6,6a,8,9,13b-hexahydronaphtho[1,2-a][3]benzazepin-12-ol;5H-Benzo(d)naphth(2,1-b)azepin-12-ol, 11-chloro-6,6a,7,8,9,13b-hexahydro-7-methyl-, (6aS,13bR)-
Solubility:
10 mM in DMSO
Storage:
-20°C Freezer
MSDS:
Inquire
Application:
Ecopipam was used for the treatment of Tourette syndrome in children.
Quality Standard:
In-house standard
Shelf Life:
2 month in rt, long time
Quantity:
Milligrams-Grams
Boiling Point:
451.9±45.0 °C | Condition: Press: 760 Torr
Density:
1.220±0.06 g/cm3 | Condition: Temp: 20 °C Press: 760 Torr
InChIKey:
DMJWENQHWZZWDF-PKOBYXMFSA-N
InChI:
InChI=1S/C19H20ClNO/c1-21-9-8-13-10-16(20)18(22)11-15(13)19-14-5-3-2-4-12(14)6-7-17(19)21/h2-5,10-11,17,19,22H,6-9H2,1H3/t17-,19+/m0/s1
Canonical SMILES:
CN1CCC2=CC(=C(C=C2C3C1CCC4=CC=CC=C34)O)Cl
Current Developer:
Ecopipam was developed by Schering plough. It has received FDA treatment of Lesch-Nyhan disease orphan drug certification.
1.Blockade of the discriminative stimulus effects of cocaine in rhesus monkeys with the D(1) dopamine antagonists SCH-39166 and A-66359.
Vanover KE;Kleven MS;Woolverton WL Behav Pharmacol. 1991 Apr;2(2):151-159.
Rhesus monkeys were trained in a 2-lever, food-reinforced drug discrimination paradigm to discriminate cocaine (0.2 or 0.4mg/kg, i.m., 10min pre-session) from saline. Before test sessions, in which responding on either lever was reinforced, the monkeys were injected with various doses of cocaine alone or in combination with the D(1) dopamine antagonists SCH-39166 or A-66359. Administration of cocaine alone (0.025-0.4mg/kg, i.m.) resulted in a dose-related increase in the percent of responses that occurred on the drug-appropriate lever. Both SCH-39166 (0.05-0.1mg/kg, i.m., 60min pre-session) and A-66359 (0.2-0.4mg/kg, i.m., 30min pre-session) reduced cocaine-appropriate responding from more than 80% to less than 20% at least at one dose combination in all monkeys. Also for both drugs and in all monkeys, the blockade was overcome by increasing the dose of cocaine. SCH-39166 was more potent and longer acting than A-66359. The results provide further evidence that D(1) dopamine receptors are involved in the discriminative stimulus effects of cocaine and that D(1) antagonists may block the subjective effects of cocaine.
2.(1-(2,5-dimethoxy-4 iodophenyl)-2-aminopropane)-induced head-twitches in the rat are mediated by 5-hydroxytryptamine (5-HT) 2A receptors: modulation by novel 5-HT2A/2C antagonists, D1 antagonists and 5-HT1A agonists.
Schreiber R;Brocco M;Audinot V;Gobert A;Veiga S;Millan MJ J Pharmacol Exp Ther. 1995 Apr;273(1):101-12.
In this study, the involvement of serotonergic and dopaminergic receptors in the modulation of the head-twitch (HTW) response to the 5-hydroxytryptamine (5-HT)2A/5-HT2C agonist, 1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane, was characterized in rats using novel and selective ligands at 5-HT2A, 5-HT2C, D1, D2 and 5-HT1A receptors. HTW were dose-dependently inhibited by the 5-HT2A/2C antagonists, ritanserin, metergoline, mesulergine, mianserin, ICI 169,369 and LY 58,537, by the preferential 5-HT2A antagonist, ketanserin and by the novel, selective 5-HT2A antagonist, SR 46349B. A further selective 5-HT2A antagonist, MDL 100,907, very potently abolished HTW (ED50 = 0.005 mg/kg). The order of relative potency correlated highly with their affinity at 5-HT2A (r = 0.83) but not 5-HT2C receptors (r = 0.06). In addition, the novel, selective 5-HT2C antagonist, SB 200,646A, failed to abolish HTW and the 5-HT2C agonists/5-HT2A antagonists, 1-(3-chlorophenyl)piperazine and 1-(3-trifluoromethylphenyl)piperazine, blocked, rather than elicited, HTW. The D1 antagonists, SCH 23390, NNC 112, NNC 756, SCH 39166 and A 69024, in this order of relative potency that correlated with their affinity at D1 receptors (r = 0.
3.New classes of selective D-1 dopamine receptor antagonist provide further evidence for two directions of D-1:D-2 interaction.
Daly SA;Waddington JL Neurochem Int. 1992 Mar;20 Suppl:135S-139S.
Initial notions of cooperative/synergistic interactions between D-1 and D-2 dopamine receptors have been followed by recent evidence suggesting more complex forms of D-1:D-2 interaction. Each of the new, putative selective D-1 antagonists SCH 39166, NO 756 and A-69024 antagonised typical behavioural responses to the selective D-2 agonist RU 24213 and concurrently released atypical behaviour. These data extend new notions of both cooperative/synergistic and oppositional D-1:D-2 interactions in the regulation of typical and atypical behaviours, which may involve further subtypes of D-1 and of D-2 receptor.
Molecular Weight Calculator Molarity Calculator Solution Dilution Calculator

Related Dopamine Receptor Products


CAS 1135278-61-3 3'-Fluorobenzylspiperone maleate

3'-Fluorobenzylspiperone maleate
(CAS: 1135278-61-3)

3'-Fluorobenzylspiperone maleate is a potent and selective ligand for the dopamine D2 receptor (Ki = 0.023 nM), displaying 2.5-fold greater affinity for D2 and ...

CAS 20012-10-6 SKF 38393 hydrobromide

SKF 38393 hydrobromide
(CAS: 20012-10-6)

SKF 38393 hydrobromide is a selective dopamine D1-like receptor partial agonist (Ki = 1, ~ 0.5, ~ 150, ~ 5000 and ~ 1000 nM for D1, D5, D2, D3 and D4 receptors,...

CAS 96333-04-9 N 0430 hydrobromide

N 0430 hydrobromide
(CAS: 96333-04-9)

N 0430 hydrobromide is a monoamine oxidase (MAO) inhibitor and a dopamine agonist.

CAS 314-19-2 (R)-(-)-Apomorphine hydrochloride

(R)-(-)-Apomorphine hydrochloride
(CAS: 314-19-2)

(R)-(-)-Apomorphine hydrochloride is the hydrochloride salt of apomorphine, which is a prototypical non-selective dopamine D2 agonist. It exhibits pKi values of...

Haloperidol hydrochloride
(CAS: 1511-16-6)

Haloperidol hydrochloride is a dopamine antagonist that specifically targets D2-like receptors, with effect to treat schizophrenia, acute psychosis, and deliriu...

CAS 15676-16-1 Sulpiride

Sulpiride
(CAS: 15676-16-1)

Sulpiride, a D2 receptor a antagonist, with antipsychotic adn antidepressant properties it can be used to treat used in schizophrenia or senile dementia etc., b...

CAS 100999-26-6 CY 208-243

CY 208-243
(CAS: 100999-26-6)

CY 208-243 is a D1DR receptor agonist and has been found to show antiparkinsonian activity in animal models.

CAS 19875-60-6 Lisuride maleate

Lisuride maleate
(CAS: 19875-60-6)

Lisuride maleate, an ergot derivative, is a nonselective dopamine receptor agonist with high affinity for D2, D3 and D4 receptors along with 5-HT1A. As an anti-...

Quick Inquiry

Verification code

Featured Items